Effect of a monoclonal antibody to sclerostin (romosozumab) on dialysis patients with osteoporosis

Effect of a monoclonal antibody to sclerostin (romosozumab) on dialysis patients with osteoporosis - Effect of romosozumab on dialysis patients with osteoporosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000040956

Enrollment

Registered

2020-09-01

Start date

2021-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure

Interventions

Intramuscularly administer 210 mg of romosozumab once a month

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: A female dialysis patient attending our hospital with osteoporosis whose radial bone density is less than 70% based on the YAM value.

Exclusion criteria

Exclusion criteria: Patients complicated with serious diseases such as malignancy, heart failure (NYHA III degrees or more), and liver cirrhosis

Design outcomes

Primary

Measure	Time frame
Radial bone density (distal 1/3, distal 1/10), bone metabolism-related markers [calcium, phosphorus, parathyroid hormone, alkaline phosphatase, bone-type alkaline phosphatase (BAP), osteocalcin (OC), I type procollagen-N-propeptide (P1NP), tartrate-resistant acid phosphatase-5b (TRACP-5b)]	—

Countries

Japan

Contacts

Public ContactMichio Kuwahara

Saitama Tsukinomori Clinic Division of Nephrology

kuwahara@k-naika-cl.jp0487921811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026